Protagonist Therapeutics Gross Profit Over Time
| PTGX Stock | USD 44.95 0.12 0.27% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Protagonist Therapeutics Performance and Protagonist Therapeutics Correlation. Protagonist |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protagonist Therapeutics. If investors know Protagonist will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protagonist Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 2.74 | Revenue Per Share 5.3 | Quarterly Revenue Growth (1.00) | Return On Assets 0.1996 | Return On Equity 0.4097 |
The market value of Protagonist Therapeutics is measured differently than its book value, which is the value of Protagonist that is recorded on the company's balance sheet. Investors also form their own opinion of Protagonist Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protagonist Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protagonist Therapeutics' market value can be influenced by many factors that don't directly affect Protagonist Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protagonist Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protagonist Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protagonist Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Gross Profit Analysis
Compare Protagonist Therapeutics and related stocks such as Revolution Medicines, Akero Therapeutics, and Avidity Biosciences Gross Profit Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RVMD | (26.6 M) | (26.6 M) | (26.6 M) | (26.6 M) | (26.6 M) | (26.6 M) | (26.6 M) | (26.6 M) | 20.2 M | (41.7 M) | (89.3 M) | 22.1 M | 25.7 M | 11.6 M | 12.2 M |
| AKRO | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | (80.2 M) | (80.2 M) | (100.9 M) | (260 K) | (29 K) | (30.4 K) |
| RNA | 379 K | 379 K | 379 K | 379 K | 379 K | 379 K | 379 K | 379 K | 379 K | (12.2 M) | 6.8 M | 9.3 M | 9.2 M | 7.5 M | 3.8 M |
| STOK | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | (450 K) | (1.9 M) | (2.2 M) | 12.4 M | 8.8 M | 9.2 M |
| KURA | (19.2 K) | (23.4 K) | (22.3 K) | (22.7 K) | (23.9 K) | (20 K) | (31 K) | (30 K) | (10 K) | (194 K) | (194 K) | (558 K) | (759 K) | (849 K) | (806.5 K) |
| MRUS | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (17.7 M) | 1.4 M | 1.4 M | 14.9 M | 35.7 M | (18.5 M) | (27.4 M) | (37.2 M) | 29.6 M | 43.9 M | 46.1 M |
| REPL | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | (148 K) | (1.8 M) | (4.1 M) | (4.6 M) | (2.4 M) | (2.7 M) | (2.8 M) |
| RLAY | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | (2.8 M) | 79.1 M | (896 K) | (2.7 M) | 20.3 M | 14.9 M |
| PLRX | 57.1 M | 57.1 M | 57.1 M | 57.1 M | 57.1 M | 57.1 M | 57.1 M | 57.1 M | 57.1 M | 57.1 M | 41.8 M | 7.6 M | 6 M | 1.6 M | 1.5 M |
| BDTX | (47 K) | (47 K) | (47 K) | (47 K) | (47 K) | (47 K) | (47 K) | (47 K) | (47 K) | (47 K) | (600 K) | (2.2 M) | (3.2 M) | (437 K) | (458.9 K) |
| ARVN | 6.7 M | 6.7 M | 6.7 M | 6.7 M | 6.7 M | 6.7 M | 6.7 M | 7.6 M | 14.3 M | 43 M | 21.8 M | 46.7 M | 131.4 M | 78.5 M | 48.1 M |
| VTYX | (30 K) | (30 K) | (30 K) | (30 K) | (30 K) | (30 K) | (30 K) | (30 K) | (30 K) | (30 K) | (30 K) | (30 K) | (470 K) | (941 K) | (894 K) |
| IDYA | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | (1.2 M) | 19.5 M | 27.9 M | 50.9 M | 19.4 M | 18.3 M |
| VRNA | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.8 M | 2.8 K | (509.8 K) | (627.8 K) | 40 M | 112 K | (679.6 K) | (645.6 K) |
| SNDX | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 627 K | 1.2 M | 2.1 M | 1.5 M | 1.5 M | 1.5 M | 139.7 M | (454 K) | (12 K) | (11.4 K) |
| TERN | (65 K) | (65 K) | (65 K) | (65 K) | (65 K) | (65 K) | (65 K) | (65 K) | (65 K) | (195 K) | (394 K) | 1000 K | (1 M) | (881 K) | (837 K) |
| XFOR | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.5 M | (672 K) | 3 M | (1.9 M) | (2 M) | (2 M) | (1.9 M) |
| ABOS | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.4 M | (4 K) | (169 K) | (42.3 M) | (40.2 M) |
| DAWN | (155 K) | (155 K) | (155 K) | (155 K) | (155 K) | (155 K) | (155 K) | (155 K) | (155 K) | (155 K) | (155 K) | (199 K) | (531 K) | (383 K) | (402.1 K) |
| HOOK | (9.8 M) | (9.8 M) | (9.8 M) | (9.8 M) | (9.8 M) | (9.8 M) | (9.8 M) | (9.8 M) | 7.6 M | 11.9 M | 19.6 M | 18.4 M | 14.2 M | 16.6 M | 12.4 M |
Protagonist Therapeutics and related stocks such as Revolution Medicines, Akero Therapeutics, and Avidity Biosciences Gross Profit description
Gross profit is a required income statement account that reflects total revenue of Protagonist Therapeutics minus its cost of goods sold. It is profit before Protagonist Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.My Equities
My Current Equities and Potential Positions
| Protagonist Therapeutics | PTGX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 44.95
Additional Tools for Protagonist Stock Analysis
When running Protagonist Therapeutics' price analysis, check to measure Protagonist Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagonist Therapeutics is operating at the current time. Most of Protagonist Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagonist Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagonist Therapeutics' price. Additionally, you may evaluate how the addition of Protagonist Therapeutics to your portfolios can decrease your overall portfolio volatility.